HELP (Helus Pharma) EBIT: $-114.81 Mil (TTM As of Dec. 2025)


HELP Helus Pharma Inc HELP
22 GF Score
Price $6.48
! 1 Warning Sign
View Full Analysis

What is Helus Pharma EBIT?

Helus Pharma HELP +7.82% 22 EBIT is $-114.81 Mil as of Dec. 2025. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Helus Pharma's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-41.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-114.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Helus Pharma's annualized ROC % for the quarter that ended in Dec. 2025 was -202.33%. Helus Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,122.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Helus Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -33.24%.

Helus Pharma  (NAS:HELP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Helus Pharma's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-164.84 * ( 1 - 0% )/( (84.132 + 78.806)/ 2 )
=-164.84/81.469
=-202.33 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=181.246 - 13.362 - ( 83.752 - max(0, 13.362 - 114.581+83.752))
=84.132

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=290.112 - 16.178 - ( 195.128 - max(0, 16.178 - 222.896+195.128))
=78.806

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Helus Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-164.84/( ( (0.125 + max(17.467, 0)) + (0.186 + max(11.59, 0)) )/ 2 )
=-164.84/( ( 17.592 + 11.776 )/ 2 )
=-164.84/14.684
=-1,122.58 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.735 + 0 + 26.094) - (13.362 + 0 + 0)
=17.467

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.766 + 0 + 23.002) - (16.178 + 0 + 0)
=11.59

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Helus Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-114.811/345.421
=-33.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma EBIT Related Terms

Helus Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Helus Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma EBIT Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial -25.52 -51.13 -38.09 -58.35 -100.03

Helus Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.39 -20.08 -24.62 -28.89 -41.21

HELP vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Helus Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helus Pharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Helus Pharma's EV-to-EBIT falls into.


HELP
22GF Score
Helus Pharma Inc HELP
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-114.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-114.81 Mil mean?
Helus Pharma (HELP) has a EBIT of $-114.81 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Helus Pharma.
Is Helus Pharma's EBIT too high?
Helus Pharma's current EBIT is $-114.81 Mil. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's EBIT compare to VRTX and REGN?
Helus Pharma's EBIT of $-114.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Helus Pharma. Helus Pharma's current EBIT is $-114.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current EBIT of $-114.81 Mil. The current EBIT is $-114.81 Mil. Helus Pharma's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Helus Pharma (HELP), the current EBIT is $-114.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score

Get the complete analysis for HELP

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.48
Price